Gastric AdenocarcinomaPhase 2NCT07912957
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
A Phase 2 study testing Trastuzumab Rezetecan (SHR-A1811) and Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab in people with Gastric Adenocarcinoma and Gastroesophageal Junction (GEJ) Adenocarcinoma, run by Fudan University at 1 site in China.
Trial summary
This single-center, dual-cohort, exploratory phase II trial evaluates the efficacy and safety of trastuzumab rezetecan (SHR-A1811), an anti-HER2 antibody-drug conjugate (ADC), with or without the anti-PD-L1 antibody adebrelimab as neoadjuvant therapy in patients with locally advanced, resectable esophageal, gastric… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- What is being tested?
- Trastuzumab Rezetecan (SHR-A1811) and Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 1 siteChina
- Study dates
- 1 Nov 2026to 31 Oct 2029
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntary signed informed consent and willingness to comply with protocol requirements.
- Age ≥18 years at the time of informed consent signing; both sexes eligible.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 7 days before study drug administration.
- Resectable locally advanced esophageal or gastric adenocarcinoma, as determined by the investigator, staged as cT1b-2 N+ M0 or cT3-4 Nany M0 (AJCC 8th edition).
- Note: Bone scan is required if bone lesions are suspected; diagnostic laparoscopy is required if peritoneal metastasis is suspected or for Lauren diffuse-type tumors.
- 5. HER2 intermediate-to-high expression by immunohistochemistry (IHC) 2+ or 3+. 6. No prior antitumor therapy for esophageal or gastric adenocarcinoma. 7. Availability of tumor tissue (primary tumor or metastatic lymph node) for pathological testing, including paraffin block, paraffin-embedded sections, or fresh tissue sections; archival tissue is preferred. If unavailable, a new baseline biopsy is required.
Show all 18Show fewer
- 8. No severe cardiac dysfunction; left ventricular ejection fraction (left ventricular ejection fraction, LVEF) ≥55% within 28 days before study drug administration.
- 9. Adequate organ function within 7 days before study drug administration, defined as:
- Hematologic function:
- Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L Platelet count ≥100 × 10⁹/L Hemoglobin ≥90 g/L No blood or component transfusion within 14 days before the first dose, and no treatment with hematopoietic growth factors (e.g., granulocyte colony-stimulating factor (G-CSF) , erythropoietin) within 7 days before the first dose.
- Hepatic function:
- Total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.
- Renal function:
- Serum creatinine (Cr) ≤1.5 × ULN, or creatinine clearance (CrCl) ≥50 mL/min (calculated by the Cockcroft-Gault formula).
- Coagulation function:
- International normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (APTT) ≤1.5 × ULN (except for patients receiving therapeutic anticoagulation).
- Urinalysis:
- Urine protein <2+; if urine protein ≥2+, 24-hour urine protein must be ≤1 g. 10. Male participants and women of childbearing potential (including premenopausal women and women within 2 years after menopause) must agree to use effective contraception from the time of informed consent signing until 6 months after the last dose of study drug. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose of study drug.
Who cannot join
- Pathological diagnosis of HER2-negative esophageal or gastric adenocarcinoma, defined as HER2 IHC 0 or 1+.
- Presence of contraindications to esophageal or gastric surgical resection.
- History of another primary malignancy, except for: basal cell carcinoma of the skin, superficial bladder cancer (Ta, non-invasive), squamous cell carcinoma of the skin, or carcinoma in situ of the cervix; or malignancies that have received curative treatment and remained recurrence-free for ≥5 years.
- Presence of non-regional lymph node or distant organ metastasis. For suspected peritoneal carcinomatosis or ascites on imaging, histological or cytological confirmation via laparoscopy or other procedures is required.
- Significant clinically meaningful bleeding or definite bleeding tendency within 1 month before informed consent, such as gastrointestinal bleeding or fecal occult blood ≥2+ (positive); or endoscopically, radiologically, or highly suspected esophageal fistula or gastric perforation.
- Any serious or uncontrolled systemic disease at the discretion of the investigator, including uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg), uncontrolled diabetes mellitus, or signs of active bleeding.
Show all 14Show fewer
- Serious cardiovascular or cerebrovascular disease, including but not limited to: NYHA class II or greater heart failure; myocardial infarction or cerebrovascular accident (cerebral ischemia, symptomatic cerebral infarction, etc.) within 3 months before the first dose; grade ≥2 persistent arrhythmia (per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ); atrial fibrillation of any grade; unstable arrhythmia or unstable angina within 1 month before the first dose in patients with coronary artery disease; congestive heart failure not meeting the above criteria; or symptomatic superior vena cava syndrome.
- Evidence of active infection, including hepatitis B (HBsAg positive with HBV DNA ≥2000 IU/mL, after excluding drug-induced or other causes of hepatitis), hepatitis C (anti-HCV antibody positive with HCV RNA above the lower limit of detection), or human immunodeficiency virus (HIV) infection; or uncontrolled active bacterial, viral, fungal, rickettsial, or parasitic infection unless treated and resolved before study drug administration.
- History of hypersensitivity to any component of the study drugs, or history of grade ≥3 hypersensitivity to macromolecular protein preparations or monoclonal antibodies.
- History of primary immunodeficiency or active autoimmune disease; or current use of immunosuppressants or systemic corticosteroids (≥10 mg/day prednisone or equivalent) that continued within 2 weeks before enrollment.
- Note: Patients with type 1 diabetes mellitus, stable hypothyroidism on hormone replacement therapy (including hypothyroidism due to autoimmune thyroid disease), psoriasis not requiring systemic treatment, or vitiligo are eligible.
- History of interstitial pneumonia, radiation pneumonitis, severe chronic obstructive pulmonary disease, severe pulmonary dysfunction, or symptomatic bronchospasm.
- Breastfeeding women unwilling to use adequate contraception during the study and for 6 months after the last dose of study drug.
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment in this clinical trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Fudan University Shanghai Cancer Center
Shanghai, 200032
Kuaile Zhao, 86-18017312534, kuaile_z@fudan.edu.cn
Haiquan Chen
About this study
Official title: A Dual-Cohort, Exploratory Study of Trastuzumab Rezetecan (SHR-A1811) With or Without Adebrelimab as Neoadjuvant Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
This single-center, dual-cohort, exploratory phase II trial evaluates the efficacy and safety of trastuzumab rezetecan (SHR-A1811), an anti-HER2 antibody-drug conjugate (ADC), with or without the anti-PD-L1 antibody adebrelimab as neoadjuvant therapy in patients with locally advanced, resectable esophageal, gastric, or gastroesophageal junction (GEJ) adenocarcinoma. Approximately 62 patients aged ≥18 years with pathologically confirmed resectable disease (cT1b-2N+M0 or cT3-4NanyM0, American Joint Committee on Cancer [AJCC] 8th edition), HER2 intermediate-to-high expression (immunohistochemistry [IHC] 2+ or 3+), no prior systemic antitumor therapy for esophageal or gastric adenocarcinoma, and Eastern Cooperative Oncology Group (ECOG) performance status 0-1 are planned for enrollment. Eligible participants will be randomly assigned to receive either trastuzumab rezetecan monotherapy or trastuzumab rezetecan plus adebrelimab for 3 cycles (each cycle 21 days), followed by radical surgery. The primary endpoint is pathological complete response (pCR). Secondary endpoints include major pathological response (MPR), R0 resection rate, objective response rate (ORR), event-free survival (EFS), overall survival (OS), and safety. Exploratory objectives include biomarker analysis to identify predictors of response to HER2 ADC therapy with or without PD-L1 blockade.
- Being tested
- Trastuzumab Rezetecan (SHR-A1811), Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab
- Keywords
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, HER2, Neoadjuvant, Trastuzumab Rezetecan
- Medical subject headings
- Adenocarcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Trastuzumab Rezetecan (SHR-A1811)Drug
Trastuzumab rezetecan for injection, an anti-HER2 antibody-drug conjugate (ADC). Administered as 4.8 mg/kg intravenous infusion (IV) on Day 1 of each 21-day cycle (Q3W), for 3 neoadjuvant cycles before radical surgery. In patients without progression who achieve R0 resection, the same dose and schedule are continued as adjuvant therapy.
Trastuzumab Rezetecan (SHR-A1811) + AdebrelimabDrug
Trastuzumab rezetecan (SHR-A1811) is an anti-HER2 ADC administered at 4.8 mg/kg IV on Day 1 of each 21-day cycle (Q3W). Adebrelimab is a humanized anti-PD-L1 monoclonal antibody administered at 1200 mg IV on Day 1 of each 21-day cycle (Q3W). Both agents are given concurrently for 3 neoadjuvant cycles before radical surgery. In patients who undergo R0 resection without disease progression, the same regimen and schedule are continued as adjuvant therapy.
| Study group | Role | What they receive |
|---|---|---|
| Trastuzumab rezetecan monotherapy | Experimental | Participants in this cohort will receive trastuzumab rezetecan (SHR-A1811) 4.8 mg/kg intravenously on day 1 of each 21-day cycle, for a total of 3 cycles as neoadjuvant therapy, followed by radical surgery. Receives: Drug: Trastuzumab Rezetecan (SHR-A1811) |
| Trastuzumab rezetecan + Adebrelimab | Experimental | Participants in this cohort will receive trastuzumab rezetecan (SHR-A1811) 4.8 mg/kg + adebrelimab 1200 mg intravenously on day 1 of each 21-day cycle, for a total of 3 cycles as neoadjuvant therapy, followed by radical surgery. Receives: Drug: Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological complete response (pCR) rate
Central pathological review; pCR defined as ypT0N0 (no residual viable tumor in primary tumor bed and sampled lymph nodes) per American Joint Committee on Cancer (AJCC) 9th edition
Measured: Assessed at surgery (approximately 3-4 weeks after completion of Cycle 3; each cycle is 21 days, total approximately 12-13 weeks after treatment initiation)
Secondary outcomes (6)
Major pathological response (MPR) rate
Central pathology; MPR defined as ≤10% residual viable tumor cells in primary tumor bed
Measured: Assessed at surgery (approximately 3-4 weeks after completion of Cycle 3; each cycle is 21 days, total approximately 12-13 weeks after treatment initiation)
R0 resection rate
R0 defined as microscopic margin-negative resection
Measured: Assessed at surgery (approximately 3-4 weeks after completion of Cycle 3; each cycle is 21 days, total approximately 12-13 weeks after treatment initiation)
Objective response rate (ORR)
Imaging (CT/MRI/PET-CT) per RECIST 1.1
Measured: Assessed at baseline and after 3 neoadjuvant cycles (each cycle is 21 days, total approximately 9 weeks after treatment initiation)
Event-free survival (EFS)
Time from first study drug administration to disease progression precluding surgery, recurrence, or death from any cause, whichever occurs first.
Measured: From treatment initiation to progression, recurrence, or death, assessed up to 24 months
Overall survival (OS)
The time from the date of first study drug administration (treatment initiation) to the date of death from any cause. Participants who are alive at the time of analysis will be censored at the date they were last known to be alive.
Measured: From treatment initiation to death from any cause, assessed up to 24 months
Incidence of adverse events (AEs)
Measured: From first dose to 90 days after last dose (each cycle is 21 days, total approximately 132 days after treatment initiation)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study start1 Nov 2026 (estimated)
- Primary completion31 Oct 2028 (estimated)
- Study completion31 Oct 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 62 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kuai Le Zhao, MD, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07912957
- Sponsor's protocol ID
- ESO-Shanghai 32
- Status last verified
- Oct 2026
- First submitted
- 25 Oct 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Dual-Cohort, Exploratory Study of Trastuzumab Rezetecan (SHR-A1811) With or Without Adebrelimab as Neoadjuvant Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
- ClinicalTrials.gov ID
- NCT07912957
- Acronym / sponsor ID
- ESO-Shanghai 32
- Keywords
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, HER2, Neoadjuvant, Trastuzumab Rezetecan
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 62 participants (estimated)
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 31 Oct 2028 (estimated)
- Study completion
- 31 Oct 2029 (estimated)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single-center, dual-cohort, exploratory phase II trial evaluates the efficacy and safety of trastuzumab rezetecan (SHR-A1811), an anti-HER2 antibody-drug conjugate (ADC), with or without the anti-PD-L1 antibody adebrelimab as neoadjuvant therapy in patients with locally advanced, resectable esophageal, gastric, or gastroesophageal junction (GEJ) adenocarcinoma. Approximately 62 patients aged ≥18 years with pathologically confirmed resectable disease (cT1b-2N+M0 or cT3-4NanyM0, American Joint Committee on Cancer [AJCC] 8th edition), HER2 intermediate-to-high expression (immunohistochemistry [IHC] 2+ or 3+), no prior systemic antitumor therapy for esophageal or gastric adenocarcinoma, and Eastern Cooperative Oncology Group (ECOG) performance status 0-1 are planned for enrollment. Eligible participants will be randomly assigned to receive either trastuzumab rezetecan monotherapy or trastuzumab rezetecan plus adebrelimab for 3 cycles (each cycle 21 days), followed by radical surgery. The primary endpoint is pathological complete response (pCR). Secondary endpoints include major pathological response (MPR), R0 resection rate, objective response rate (ORR), event-free survival (EFS), overall survival (OS), and safety. Exploratory objectives include biomarker analysis to identify predictors of response to HER2 ADC therapy with or without PD-L1 blockade.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Trastuzumab rezetecan monotherapy | Experimental | Drug: Trastuzumab Rezetecan (SHR-A1811)Participants in this cohort will receive trastuzumab rezetecan (SHR-A1811) 4.8 mg/kg intravenously on day 1 of each 21-day cycle, for a total of 3 cycles as neoadjuvant therapy, followed by radical surgery. |
| Trastuzumab rezetecan + Adebrelimab | Experimental | Drug: Trastuzumab Rezetecan (SHR-A1811) + AdebrelimabParticipants in this cohort will receive trastuzumab rezetecan (SHR-A1811) 4.8 mg/kg + adebrelimab 1200 mg intravenously on day 1 of each 21-day cycle, for a total of 3 cycles as neoadjuvant therapy, followed by radical surgery. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Voluntary signed informed consent and willingness to comply with protocol requirements.
- Age ≥18 years at the time of informed consent signing; both sexes eligible.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 7 days before study drug administration.
- Resectable locally advanced esophageal or gastric adenocarcinoma, as determined by the investigator, staged as cT1b-2 N+ M0 or cT3-4 Nany M0 (AJCC 8th edition).
- Note: Bone scan is required if bone lesions are suspected; diagnostic laparoscopy is required if peritoneal metastasis is suspected or for Lauren diffuse-type tumors.
Key exclusion criteria (14 listed)
- Pathological diagnosis of HER2-negative esophageal or gastric adenocarcinoma, defined as HER2 IHC 0 or 1+.
- Presence of contraindications to esophageal or gastric surgical resection.
- History of another primary malignancy, except for: basal cell carcinoma of the skin, superficial bladder cancer (Ta, non-invasive), squamous cell carcinoma of the skin, or carcinoma in situ of the cervix; or malignancies that have received curative treatment and remained recurrence-free for ≥5 years.
- Presence of non-regional lymph node or distant organ metastasis. For suspected peritoneal carcinomatosis or ascites on imaging, histological or cytological confirmation via laparoscopy or other procedures is required.
- Significant clinically meaningful bleeding or definite bleeding tendency within 1 month before informed consent, such as gastrointestinal bleeding or fecal occult blood ≥2+ (positive); or endoscopically, radiologically, or highly suspected esophageal fistula or gastric perforation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Trastuzumab Rezetecan (SHR-A1811)Trastuzumab rezetecan for injection, an anti-HER2 antibody-drug conjugate (ADC). Administered as 4.8 mg/kg intravenous infusion (IV) on Day 1 of each 21-day cycle (Q3W), for 3 neoadjuvant cycles before radical surgery. In patients without progression who achieve R0 resection, the same dose and schedule are continued as adjuvant therapy. | Drug | Trastuzumab rezetecan monotherapy |
| Trastuzumab Rezetecan (SHR-A1811) + AdebrelimabTrastuzumab rezetecan (SHR-A1811) is an anti-HER2 ADC administered at 4.8 mg/kg IV on Day 1 of each 21-day cycle (Q3W). Adebrelimab is a humanized anti-PD-L1 monoclonal antibody administered at 1200 mg IV on Day 1 of each 21-day cycle (Q3W). Both agents are given concurrently for 3 neoadjuvant cycles before radical surgery. In patients who undergo R0 resection without disease progression, the same regimen and schedule are continued as adjuvant therapy. | Drug | Trastuzumab rezetecan + Adebrelimab |
Primary outcome
Pathological complete response (pCR) rate
Time frame: Assessed at surgery (approximately 3-4 weeks after completion of Cycle 3; each cycle is 21 days, total approximately 12-13 weeks after treatment initiation)
Central pathological review; pCR defined as ypT0N0 (no residual viable tumor in primary tumor bed and sampled lymph nodes) per American Joint Committee on Cancer (AJCC) 9th edition
6 secondary outcomes
Major pathological response (MPR) rate
Time frame: Assessed at surgery (approximately 3-4 weeks after completion of Cycle 3; each cycle is 21 days, total approximately 12-13 weeks after treatment initiation)
R0 resection rate
Time frame: Assessed at surgery (approximately 3-4 weeks after completion of Cycle 3; each cycle is 21 days, total approximately 12-13 weeks after treatment initiation)
Objective response rate (ORR)
Time frame: Assessed at baseline and after 3 neoadjuvant cycles (each cycle is 21 days, total approximately 9 weeks after treatment initiation)
Event-free survival (EFS)
Time frame: From treatment initiation to progression, recurrence, or death, assessed up to 24 months
Overall survival (OS)
Time frame: From treatment initiation to death from any cause, assessed up to 24 months
Incidence of adverse events (AEs)
Time frame: From first dose to 90 days after last dose (each cycle is 21 days, total approximately 132 days after treatment initiation)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Gastric Adenocarcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer
RecruitingPhase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
RecruitingPhase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Not yet recruitingPhase 2
D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Active, not recruitingPhase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors, NSCLC
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Trastuzumab Rezetecan (SHR-A1811) and Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab in people with Gastric Adenocarcinoma and Gastroesophageal Junction (GEJ) Adenocarcinoma, run by Fudan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kuaile Zhao, M.D. (+86-18017312534, kuaile_z@fudan.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological complete response (pCR) rate (time frame: Assessed at surgery (approximately 3-4 weeks after completion of Cycle 3; each cycle is 21 days, total approximately 12-13 weeks after treatment initiation)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.